Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|October 31, 2006
Deciphering leukemic B-cell chronic lymphoproliferative disordersValérie Ugo, Nathalie Leporrier, Véronique Salaun, et al.
Haematologica|January 28, 2017
miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization studyAnne-Laure Gagez, Isabelle Duroux-Richard, Stéphane Leprêtre, et al.
Blood|June 28, 2019
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group studyAnne Quinquenel, Luc-Matthieu Fornecker, Rémi Letestu, et al.
Hemasphere|October 16, 2020
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)Anne Quinquenel, Thérèse Aurran-Schleinitz, Aline Clavert, et al.
Blood Advances|November 29, 2021
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemiaCristina Bagacean, Rémi Letestu, Chadi Al-Nawakil, et al.
The Lancet. Haematology|December 25, 2017
Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 studyCaroline Dartigeas, Eric Van Den Neste, Julie Léger, et al.
Leukemia & Lymphoma|July 4, 2015
Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemiaCaroline Dartigeas, Eric Van Den Neste, Christian Berthou, et al.
Human Mutation|April 14, 2025
The Broad Spectrum of TP53 Mutations in CLL: Evidence of Multiclonality and Novel Mutation HotspotsGrégory Lazarian, Bernard Leroy, Floriane Theves, et al.
Leukemia|September 16, 2020
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemiaRémi Letestu, Abdelmalek Dahmani, Marouane Boubaya, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Pageof 4